Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

305 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Long-term efficacy and safety of subcutaneous pasireotide in acromegaly: results from an open-ended, multicenter, Phase II extension study.
Petersenn S, Farrall AJ, De Block C, Melmed S, Schopohl J, Caron P, Cuneo R, Kleinberg D, Colao A, Ruffin M, Hermosillo Reséndiz K, Hughes G, Hu K, Barkan A. Petersenn S, et al. Among authors: ruffin m. Pituitary. 2014 Apr;17(2):132-40. doi: 10.1007/s11102-013-0478-0. Pituitary. 2014. PMID: 23529827 Free PMC article. Clinical Trial.
Pasireotide versus octreotide in acromegaly: a head-to-head superiority study.
Colao A, Bronstein MD, Freda P, Gu F, Shen CC, Gadelha M, Fleseriu M, van der Lely AJ, Farrall AJ, Hermosillo Reséndiz K, Ruffin M, Chen Y, Sheppard M; Pasireotide C2305 Study Group. Colao A, et al. Among authors: ruffin m. J Clin Endocrinol Metab. 2014 Mar;99(3):791-9. doi: 10.1210/jc.2013-2480. Epub 2014 Jan 13. J Clin Endocrinol Metab. 2014. PMID: 24423324 Free PMC article. Clinical Trial.
Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-blind, multicenter, Phase III study.
Sheppard M, Bronstein MD, Freda P, Serri O, De Marinis L, Naves L, Rozhinskaya L, Hermosillo Reséndiz K, Ruffin M, Chen Y, Colao A. Sheppard M, et al. Among authors: ruffin m. Pituitary. 2015 Jun;18(3):385-94. doi: 10.1007/s11102-014-0585-6. Pituitary. 2015. PMID: 25103549 Free PMC article. Clinical Trial.
Erratum to: Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-blind, multicenter, Phase III study.
Sheppard M, Bronstein MD, Freda P, Serri O, De Marinis L, Naves L, Rozhinskaya L, Hermosillo Reséndiz K, Ruffin M, Chen Y, Colao A. Sheppard M, et al. Among authors: ruffin m. Pituitary. 2015 Jun;18(3):395-6. doi: 10.1007/s11102-014-0628-z. Pituitary. 2015. PMID: 25566750 Free PMC article. No abstract available.
Switching patients with acromegaly from octreotide to pasireotide improves biochemical control: crossover extension to a randomized, double-blind, Phase III study.
Bronstein MD, Fleseriu M, Neggers S, Colao A, Sheppard M, Gu F, Shen CC, Gadelha M, Farrall AJ, Hermosillo Reséndiz K, Ruffin M, Chen Y, Freda P; Pasireotide C2305 Study Group. Bronstein MD, et al. Among authors: ruffin m. BMC Endocr Disord. 2016 Apr 2;16:16. doi: 10.1186/s12902-016-0096-8. BMC Endocr Disord. 2016. PMID: 27039081 Free PMC article. Clinical Trial.
A Mail-Based HPV Self-Collection Program to Increase Cervical Cancer Screening in Appalachia: Results of a Group Randomized Trial.
Reiter PL, Shoben AB, Cooper S, Ashcraft AM, McKim Mitchell E, Dignan M, Cromo M, Walunis J, Flinner D, Boatman D, Hauser L, Ruffin MT, Belinson JL, Anderson RT, Kennedy-Rea S, Paskett ED, Katz ML. Reiter PL, et al. Among authors: ruffin mt. Cancer Epidemiol Biomarkers Prev. 2024 Oct 24. doi: 10.1158/1055-9965.EPI-24-0999. Online ahead of print. Cancer Epidemiol Biomarkers Prev. 2024. PMID: 39445831
305 results